Docket No.: ABB1130P0901US

6475.US.02 (WP/1587)

The Office Action

The Office Action made the following rejection:

1) claims 1, 3 and 7-12 were rejected under 35 U.S.C. §103(a) as being unpatentable over

Lacy et al. (U.S. Patent No. 5,645,856).

Discussion of 35 U.S.C. §103(a) Rejection

The Examiner has rejected claims 1, 3 and 7-12 under 35 U.S.C. §103(a) as being

unpatentable over Lacy et al. The Examiner stated that "Lacy et al. (U.S. Patent No. 5,645,856)

teaches a carrier system for a hydrophobic drug (including fenofibrate) composition comprising (a)

a digestible oil (including soybean oil, coconut oil, corn oil, palm oil, cottonseed oil, olive oil,

safflower seed oil); (b) a pharmaceutically acceptable surfactant comprising a hydrophilic (including

phospholipids, polyoxyethylene sorbitan fatty acid derivatives, castor oil or hydrogenated ester

castor oil ethoxylates, fatty acid ethoxylates, alcohol ethoxylates, polyoxyethylene-

polyoxypropylene co-polymers and block co-polymers) and a lipophilic surfactant (including

propylene glycol), see in particular col. 3, lines 38-67, cols. 5-9 and col. 11, lines 22-23, see col. 21,

example 6, lines 21-31."

Lacy et al. does teach a carrier system for a hydrophobic drug comprising (a) a digestible oil

and (b) a pharmaceutically acceptable surfactant comprising a hydrophilic surfactant component and

a lipophilic surfactant component. Lacy et al. describe the surfactant as being capable of

"dispersing" the oil in vivo upon administration, said surfactant comprising a hydrophilic surfactant

2

Docket No.: ABB1130P0901US 6475.US.02 (WP/1587)

component, and being such that it does not substantially inhibit the lipolysis of the oil. Lacy et al.,

in a preferred aspect, still further describe the surfactant as comprising a hydrophilic surfactant

component which substantially inhibits the in vivo lipolysis of a digestible oil and a lipophilic

surfactant component capable of at least substantially reducing said inhibitory effect of said

hydrophilic surfactant component (col. 3, lines 38-67).

The present invention, as described in claim 1, provides a composition consisting essentially

of a fibrate dissolved in at least one oil with one selected emulsifier, and being such that the

emulsifier does not exhibit or demonstrate the property of "not substantially inhibiting the lipolysis

of the oil." The emulsifier does not contain a hydrophilic surfactant component that substantially

inhibits the in vivo lipolysis of an oil, and a lipophilic surfactant component capable of at least

substantially reducing said inhibitory effect of said hydrophilic surfactant component. Fibrates are

simply dissolved in at least one oil with one selected emulsifier; there is no requirement for a

surfactant that does not substantially inhibit lipolysis. The inclusion of a surfactant that does not

substantially inhibit lipolysis of an oil is an important property of Lacy's compositions

(col. 3, lines 38-45 and claim 1); this is NOT a property of the presently claimed invention.

The Examiner also stated, "Note that the addition or subtraction of a pharmaceutical auxiliary

or excipient, such as a surfactant (emulsifier), is within the purview of the skilled artisan and is

therefore obvious, absent evidence to the contrary."

3

Docket No.: ABB1130P0901US

6475.US.02 (WP/1587)

The surfactant of Lacy's compositions is not simply a pharmaceutical "auxiliary," but the

basis and foundation of the described carrier for hydrophobic drugs. Thus, it would not have been

obvious to one of ordinary skill in the art to employ a composition consisting essentially of a fibrate

dissolved in at least one oil with one recited emulsifier.

In view of the above remarks, withdrawal of this rejection is requested.

Claims 16-18 which are directed to a non-elected invention have been canceled. Applicants

reserve the right to file a divisional application thereto.

Summary

Favorable consideration and allowance of claims 1, 3 and 7-12 is respectfully requested.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER

Date: October 3, 2002

Martin I Katz Reo No. 25.0

Citicorp Center, Suite 3800

500 W. Madison

Chicago, IL 60661-2511

(312) 876-1800

4